Session » (0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0274

A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab

9:00AM-11:00AM: Abstract Number: 0264

A Novel Role for Rheumatologists: Managing Idiopathic Granulomatous Mastitis

9:00AM-11:00AM: Abstract Number: 0257

Activity of IgG4-related Disease Differs Depending on the Presence or Absence of Concomitant Hypocomplementemia

9:00AM-11:00AM: Abstract Number: 0269

Acute Kidney Injury and Plasma Cell-Rich Acute Interstitial Nephritis in VEXAS Syndrome: An Under-recognized Disease Feature

9:00AM-11:00AM: Abstract Number: 0277

Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 0252

Characterizing Granulomatous Mastitis: A Retrospective, Single-Institutional Case Series of a Racially and Ethnically Diverse Cohort

9:00AM-11:00AM: Abstract Number: 0253

Clinical Phenotypes in Patients with Isolated Anti-Sm/RNP Common Motif Antibody Positivity, Compared to Those with or Without Associated Anti-RNP Antibody Reactivity

9:00AM-11:00AM: Abstract Number: 0262

Destructive Arthritis in Whipple Disease. a Single-center Case Series of 14 Patients

9:00AM-11:00AM: Abstract Number: 0261

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results

9:00AM-11:00AM: Abstract Number: 0265

Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing

9:00AM-11:00AM: Abstract Number: 0273

Disease Characteristics and Pancreatic Damage in IgG4-Related Disease with Pancreatic Involvement

9:00AM-11:00AM: Abstract Number: 0276

Disease Control in Patients with Monogenetic Autoinflammatory Diseases Under Canakinumab Treatment – Comparison of 30 Months Interim Data from the RELIANCE Registry

9:00AM-11:00AM: Abstract Number: 0282

DNA Methylation Markers in Peripheral Blood as Effective Diagnostic Biomarkers for Adult-onset Still’s Disease

9:00AM-11:00AM: Abstract Number: 0266

E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 0270

Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety

9:00AM-11:00AM: Abstract Number: 0280

Immunosuppression in the Treatment of Susac Syndrome: A Retrospective Evaluation of the Largest Cohort of Susac Syndrome

9:00AM-11:00AM: Abstract Number: 0281

Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?

9:00AM-11:00AM: Abstract Number: 0255

Lymphoid Mass in the Inferior Turbinate with IgG4 Producing Cells: A Nasal Manifestation of IgG4-RD or a Distinct Chronic Inflammatory Disease?

9:00AM-11:00AM: Abstract Number: 0254

Microvascular and Cutaneous Assessment in Adult Patients with Hypermobile Ehlers-Danlos Syndrome

9:00AM-11:00AM: Abstract Number: 0256

Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study

9:00AM-11:00AM: Abstract Number: 0275

No Cumulative Effect of Infection Rates in Children Receiving Long-term Canakinumab Treatment in Autoinflammatory Periodic Fever Syndromes − Data from the RELIANCE Registry

9:00AM-11:00AM: Abstract Number: 0278

NOD2 Genotyping Landscape in Yao Syndrome

9:00AM-11:00AM: Abstract Number: 0263

Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 0260

Phenotypes of the Patients with More Than One Autoinflammatory Gene Variant: Classified Diseases and Mixed Autoinflammatory Disorders (MAID)

9:00AM-11:00AM: Abstract Number: 0259

Preliminary Experience with a Novel “Fix” for Deep Epitope and Transcriptional Phenotyping of Fragile Cells from Autoinflammatory Flares

9:00AM-11:00AM: Abstract Number: 0272

Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study

9:00AM-11:00AM: Abstract Number: 0268

Safety and Efficacy of CT-guided Percutaneous Infra-Renal Periaortic Biopsies in Suspected Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 0271

Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients

9:00AM-11:00AM: Abstract Number: 0279

Therapeutic Exploration of Immune Checkpoint Inhibitor Induced Inflammatory Arthritis In Vivo

9:00AM-11:00AM: Abstract Number: 0258

Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation

9:00AM-11:00AM: Abstract Number: 0267

Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].